
BRAIN CANCER SYMPOSIUM

DIPG | DMG | MEDULLOBLASTOMA

BANFF, ALBERTA, CANADA
JULY 26-27, 2025



The Brooke Healey Foundation™

Helping families • Funding research • Awarding scholarships

Caring 'Til It's CURED!™



www.brookehealey.org

BRAIN CANCER SYMPOSIUM

DIPG | DMG | MEDULLOBLASTOMA

We are excited to welcome you to the 8th Brain Cancer Symposium in Banff, Alberta, Canada. This one-of-a-kind event brings together doctors, researchers, families, and foundations to collaborate and work together to advance pediatric brain cancer research. Our unique approach develops collaborations with researchers and funders to support the great work. The results of this approach have shown great advancements in DIPG/DMG and medulloblastoma research. You are part of this revolution in innovation.

By the numbers, what you are joining is part of an 18-year strategy that has resulted in over 170 projects in 29 countries and nearly $40 million in research funding and support from the partner organizations in this group! Specifically, at this symposium you are part of:

- 244 foundation and research experts
- 97 learning sessions
- 83 independent foundations and chapters
- 45 different hospitals and institutions
- 8 industry partners
- 111 speakers
- 10 countries
- 3 track sessions

All resulting in the best homerun research worldwide!

We also encourage you to join us at the next Symposium April 15-18, 2027 in Cincinnati, Ohio, USA. There we will celebrate our 20th anniversary exactly where it originally started. Expect unparalleled sessions, exciting results, and one of our most memorable meetings in celebration of your efforts!

We would be remiss if we didn't also thank our wonderful Collaborative partners and Chapters that join together in a truly cooperative and transparent manner to put our children ahead of all other objectives. We thank our brilliant researchers not only for their wisdom, but also their dedication to a cause that often becomes personal

to them as well. We thank our sponsors for their support and their partnership to bring invention to the frontlines of this fight. We thank our families and warriors for their faith in this effort and sharing their children's stories to offer a personal face to this battle. We thank our Medical Advisory Council, moderators, staff, and planning members for making this event impactful and focused. It wouldn't be possible without everyone's dedication.

Sincerely,
DIPG/DMG Symposium Planning Committee

CANADIAN COMMITTEE

Cari Comboye
Yuki Iwakawa
Amanda Nevesely
Lindsay Walper

COLLABORATIVE COMMITTEE

Michelle Edenfield
Tamara Ekis
Steve Healey
Christy Jennings
Brooke Nicholas
Jay Nicholas

EXECUTIVE COMMITTEE

Gavin Baumgardner, DO
Robert Beaver
Jackie Criswell
Brooke Desserich
Grace Desserich
Keith Desserich
Christy Drinnen
Melissa Fleming
Molly Fogle
Brooke George
Jim Getgey
Courtney Siegel
Heidi Varns
Shae Vasile-Beaver
Mike Weiner
Katie Zimmerman

SPECIAL THANKS TO OUR SPONSORS

DIAMOND

THE CURE STARTS NOW®

The Brooke Healey Foundation

THE CURE STARTS NOW® AUSTRALIA

THE CURE STARTS NOW® CANADA

PLATINUM

choose Joy for Melina
The Melina Michelle Edenfield Foundation

Reflections Of Grace Foundation

GOLD

CHIMERIX® | Jazz Pharmaceuticals.

Chimerix is now part of Jazz Pharmaceuticals

SNAPGRANT™
the uncommon, common app for grant research



THE CURE STARTS NOW®
CANADA

Families across the globe fighting for the same cause;

THE CURE FOR ALL CANCERS!

The Cure Starts Now Canada funds critical childhood brain cancer research, including that of Dr. Cynthia Hawkins at Sick Kids and Dr. Jerome Fortin from McGill University, in an effort to put an end to cancer. We are proud to partner with members of the DIPG/DMG Collaborative and hundreds of families all over the world for this important cause.

Learn more about our families and our mission at
thecurestartsnow.ca

DIPG/DMG Collaborative
VISIONARY PARTNER
2025
Member

PROGRAM SCHEDULE

Agenda is subject to change. The printed version may differ from the online version. If there is a discrepancy, please refer to the online version of the agenda.

DIAMOND SPONSORS

PLATINUM SPONSORS

GOLD SPONSORS

SILVER SPONSORS

BRONZE SPONSORS

WARRIOR SPONSORS

DIPG/DMG COLLABORATIVE

VISIONARY PARTNERS

LEADERSHIP PARTNERS

RESEARCH PARTNERS

SPONSORS

SPEAKER'S NOTES

Please deliver slides in final form no later than 7:00am the day of the presentation via flash drive. To send in advance, please email to **symposium@thecurestartsnow.org.**

PRESENTATION REHEARSALS IN ANGUS ROOM (SAT-SUN)

THURSDAY, JULY 24

CHAPTER WORKSHOPS

6:00pm – 8:00pm	**The Cure Starts Now Chapter Reception**	New Brunswick Room

FRIDAY, JULY 25

Transport shuttle schedule:
6:45am - From Hotel Canoe lobby to Fairmont
6:00pm - From Hotel Canoe lobby to Fairmont
9:00pm - From Fairmont lobby to Hotel Canoe

We recommend using the earlier shuttle to avoid capacity issues as there are limited shuttles.

GENERAL ATTENDEES

4:00pm – 5:30pm	**General Registration**	Ivor Petrak Room
5:30pm – 9:00pm	**Welcome Reception** sponsored by	Ivor Petrak Room

CHAPTER WORKSHOPS

6:30am – 7:30am	**Working Breakfast** sponsored by	Alhambra Hall
7:00am – 1:30pm	**The Cure Starts Now Chapter Meeting**	Alhambra Hall
12:30pm – 1:30pm	**Working Lunch** sponsored by	Alhambra Hall
1:30pm – 5:30pm	**The Cure Starts Now Ancillary Event: Tour of Bow Falls & Lake Louise** sponsored by	Meet in Lobby
5:30pm – 9:00pm	**The Cure Starts Now Welcome Reception - 5-Pin Bowling** sponsored by	Banff Springs Bowling Centre

MEDICAL ADVISORY COUNCIL

6:30am – 7:30am	**Working Breakfast** sponsored by	Oak Room
7:00am – 1:30pm	**MAC Workshop**	Oak Room
12:30pm – 1:30pm	**Working Lunch** sponsored by	Oak Room
1:30pm – 5:30pm	**The Cure Starts Now Ancillary Event: Tour of Bow Falls & Lake Louise** sponsored by	Meet in Lobby
5:30pm – 9:00pm	**The Cure Starts Now Welcome Reception - 5-Pin Bowling** sponsored by	Banff Springs Bowling Centre

Agenda is subject to change. The printed version may differ from the online version. If there is a discrepancy, please refer to the online version of the agenda.

SCAN TO VIEW THE ONLINE AGENDA

SATURDAY, JULY 26

Transport shuttle schedule:
6:00am - 7:00am From Hotel Canoe lobby to Fairmont
9:30pm - 10:30pm From Fairmont lobby to Hotel Canoe

We recommend using the earlier shuttle to avoid capacity issues as there are limited shuttles.

GENERAL ATTENDEES

6:30am – 7:30am	**Breakfast Available in Foyer** sponsored by	Alhambra Hall
7:30am – 7:45am	**Welcome Address** *Speakers: Steve Healey, Tamara Ekis, Keith Desserich*	Alhambra Hall
7:45am – 8:30am	**Review of DIPG/DMG Data Collection Efforts** *Moderators: Stewart Goldman*	Alhambra Hall
8:00am – 8:15am	**SIOPe DIPG/DMG Registry Update** *Speakers: Sophie Veldhuijzen van Zanten*	Alhambra Hall
8:15am – 8:30am	**International DIPG/DMG Registry Update** *Speakers: Trent Hummel*	Alhambra Hall
8:30am – 8:50am	**A Review of PBTC Initiatives for DIPG/DMG and Medulloblastoma** *Speakers: Ira Dunkel*	Alhambra Hall
8:50am – 9:10am	**Reirradiation for DIPG: Common Practice but is it Ready for Standard of Care?** *Speakers: Katherine Warren*	Alhambra Hall
9:10am – 9:25am	**Coffee and Tea Break** sponsored by	Alhambra Hall
9:25am – 9:30am	**Review of Current Funded Research Results and Progress** *Speakers: Gavin Baumgardner*	Alhambra Hall
9:30am – 9:45am	**Translating Mechanism to Patient Benefit for ACVR1 Mutant DIPG** *Speakers: Chris Jones*	Alhambra Hall
9:45am – 10:00am	**CSF Cell-Free Tumor DNA Liquid Biopsies** *Speakers: Alexandra Miller*	Alhambra Hall
10:00am – 10:15am	**Targeting Histone Lysine Demethylases to Treat DIPG** *Speakers: Richard Lu*	Alhambra Hall
10:15am – 10:30am	**Exploring Novel Targets in DIPG** *Speakers: Biplab Dasgupta*	Alhambra Hall
10:30am – 10:45am	**The Role of QPRT and NAD Pathways in DIPG Treatment Resistance** *Speakers: Ian Pollack*	Alhambra Hall
10:45am – 11:00am	**Targeting Post-Translational Protein Modification to Halt DIPG Tumorgenicity** *Speakers: Benjamin Rayner*	Alhambra Hall
11:00am – 11:15am	**A Novel Formulation Targeting MYCN Expression and Copper Chelation to Treat DIPG** *Speakers: Riccardo Cazzoli*	Alhambra Hall
11:15am – 11:30am	**Enhancing the Recruitment of Tumor Infiltrating Lymphocytes to Improve DMG Therapies** *Speakers: Matthew Dun*	Alhambra Hall
11:30am – 11:45am	**DMG COMBATT 2.0** *Speakers: Ryan Duchatel*	Alhambra Hall
11:45am – 12:00pm	**TarGeT** *Speakers: Nicholas Gottardo*	Alhambra Hall
12:00pm – 12:25pm	**Working Lunch** sponsored by	Alhambra Hall
12:25pm – 12:55pm	**Cure Fund Grant Presentation** sponsored by SNAPGRANT *Moderators: Gavin Baumgardner* *Speakers: Pablo Acera, Esther Hulleman, Rosa Mistica Ignacio, Ashlee Harris*	Alhambra Hall
12:55pm – 1:00pm	**Review of Current Funded Research Results and Progress** *Speakers: Gavin Baumgardner*	Alhambra Hall
1:00pm – 1:15pm	**SUMOylation as a Novel Target in DIPG** *Speakers: Biplab Dasgupta*	Alhambra Hall
1:15pm – 1:30pm	**Targeting Macrophages to Improve Survival with DIPG** *Speakers: Dolores Hambardzumyan*	Alhambra Hall
1:30pm – 1:45pm	**Synthetic Lethality Screening with Methionine Restriction for DIPG** *Speakers: Cynthia Hawkins*	Alhambra Hall
1:45pm – 2:00pm	**Starve the Monster: Multi-Metabolic Treatment Strategies for H3.3K27M-Mutant DIPG/DMG** *Speakers: Christof Kramm*	Alhambra Hall
2:00pm – 2:15pm	**Assessing the Potential of the HDAC Inhibitor Givinostat and Radiotherapy for the Treatment of DMG** *Speakers: Esther Hulleman*	Alhambra Hall

2:15pm – 2:30pm	**Preclinical Evaluation of TP-0184 in an Autochthonous Mouse Model in DIPG** *Speakers: Oren Becher*	Alhambra Hall
2:30pm – 2:45pm	**Targeted Radiopharmaceutical Therapies for Pediatric Brain Tumors; TARGET-FIRST** *Speakers: Sophie Veldhuijzen van Zanten*	Alhambra Hall
2:45pm – 3:00pm	**Intranasal Delivery of Targeting Nanotherapeutics for DIPG** *Speakers: Rintaro Hashizume*	Alhambra Hall
3:00pm – 3:15pm	**FLASH Radiotherapy** *Speakers: Anthony Mascia*	Alhambra Hall
3:15pm – 3:30pm	**Targeting DMG with Innovative T-Cell Immunotherapy** *Speakers: Richard Lu*	Alhambra Hall
3:30pm – 3:45pm	**Group Photo**	Terrace
3:45pm – 4:00pm	**Snack Break** sponsored by Reflections Of Grace Foundation	Alhambra Hall
4:00pm – 5:10pm	**Therapeutic Showcase** sponsored by THE CURE STARTS NOW *Speakers: Gavin Baumgardner*	Alhambra Hall
5:10pm – 5:15pm	**Wrap Up** *Speakers: Gavin Baumgardner, Tamara Ekis*	Alhambra Hall
6:00pm – 7:00pm	**Hospitality Suite** sponsored by	Cascade/Conservatory Room

FAMILIES & FOUNDATIONS

9:10am – 9:25am	**Coffee and Tea Break** sponsored by THE CURE STARTS NOW	
9:25am – 10:45am	**Statistical Analysis and Trial Design** sponsored by *Speakers: Felicia Wilson*	Alberta Room
12 00pm – 12 25pm	**Working Lunch** sponsored by	Alhambra Hall
12:55pm – 3:30pm	**Family/Foundations Workshop** sponsored by Reflections Of Grace Foundation *Speakers: Steve Healey, Tamara Ekis*	Alberta Room

ADULT & YOUNG ADULT GROUP (INVITATION ONLY)

10:45am – 12:00pm	**Young Adult and Adult DIPG/DMG Focus Group (Invitation Only)**	Alberta Room

TICKET ONLY EVENTS

7:00pm 10:00pm	**Networking Dinner** sponsored by THE CURE STARTS NOW	Cascade/Conservatory Room

The ACTION Study

Dordaviprone (ONC201) in newly diagnosed H3 K27M-mutant diffuse glioma

Eligibility Criteria

- H3 K27M-mutant diffuse glioma, H3 K27M mutation by IHC or NGS
- ≥10 kg body weight
- Completed radiotherapy within 2 to 6 weeks prior to randomization
- KPS/LPS ≥70
- Stable or decreasing corticosteroids and anti-seizure medication for seven days
- Not eligible: Spinal tumors, DIPG, leptomeningeal spread, CSF dissemination

1:1:1 Randomization (2–6 weeks post RT)

- Dordaviprone (625 mg) Twice-weekly
- Dordaviprone (625 mg) Once-weekly
- Placebo

Eligibility will not be restricted based on age, provided patients are ≥10 kg. Patients ≤52.5 kg will receive a dose scaled by body weight.

The ACTION study (NCT05580562) is a randomized, double-blind, placebo-controlled, parallel-group international Phase 3 trial of patients with newly diagnosed, H3 K27M-mutant diffuse glioma after completion of radiotherapy[1]

Primary Outcomes:

- Efficacy: OS, PFS

Study Status:

- ACTION is open at more than 140 centers globally and is enrolling throughout Europe, Israel, South America, and Asia-Pacific.
- An up-to-date list of study sites is available at clinicaltrials.gov (NCT05580562).
- Funding is available for eligible patients who must travel for treatment; contact clinicaltrials@chimerix.com for more information.

References:

(1) Arrillaga Romany I et al. *Neuro Oncol*. 2024;26(S2):S173-S181

Dordaviprone is an investigational product and its safety and effectiveness as a treatment for recurrent H3 K27M-mutant diffuse glioma is currently being investigated. Dordaviprone is not currently approved for use by the FDA, or any other health authority.

CHIMERIX® A Jazz Pharmaceuticals Company

SUNDAY, JULY 27

Transport shuttle schedule:
6:00am - 7:00am From Hotel Canoe lobby to Fairmont
9:30pm - 10:30pm From Fairmont lobby to Hotel Canoe

We recommend using the earlier shuttle to avoid capacity issues as there are limited shuttles.

GENERAL DIPG/DMG SESSIONS - ALHAMBRA HALL

6:15am – 7:30am	**Breakfast Available** sponsored by
7:30am – 8:00am	**Registry Patterns and Trends; What is Missing?** *Speakers: Trent Hummel*
8:00am – 10:50am	**Review of Newly Funded DMG Research Concepts** *Moderators: Gavin Baumgardner*
8:05am – 8:20am	**Targeting DMG Vulnerabilities as a Therapeutic Strategy** *Speakers: Marta Alonso*
8:20am – 8:35am	**Understanding Tumor Heterogeneity in ACVR1-Mutated DMG** *Speakers: Jerome Fortin*
8:35am – 8:50am	**Multilamellar H3K27M RNA Aggregates Targeting DMG** *Speakers: Gene Hwang*
8:50am – 9:05am	**Targeting Lactate Production Pathways as a Novel Therapy Against DIPG** *Speakers: Jessica Bell*
9:05am – 9:20am	**Cytokine Signaling in DMG to Enhance GD2-Directed CAR T Cell Trafficking** *Speakers: Jessica Foster*
9:20am – 9:35am	**Leveraging Epigenetic Alterations for Therapy of DMG** *Speakers: Michael Koldobskiy*
9:35am – 9:50am	**CXCR1/2 Signaling Pathway: a Role in the Invasive Mechanism of DIPG** *Speakers: Oded Behar*
9:50am – 10:05am	**Harnessing Developmental Neurobiology to Reprogram the Cell of Origin of DMG** *Speakers: David Eisenstat*
10:05am – 10:20am	**Leveraging Open Science and Collaboration to Identify Clinical Quality ALK2 Inhibitors for DIPG** *Speakers: David Drewry*
10:20am – 10:35am	**Unlocking the Potential of the Blood-Brain Barrier** *Speakers: Maria Tsoli*
10:35am – 10:50am	**Summary of Newly Funded DIPG/DMG Research Concepts** *Speakers: Gavin Baumgardner*
10:50am – 11:00am	**Coffee and Tea Break** sponsored by
11:00am – 12:05pm	**Review of Current Funded Research Results and Progress** *Moderators: Gavin Baumgardner*
11:05am – 11:20am	**Preclinical Assessment of Efficacy and Specificity of Logic-Gates CAR-T Cell Therapy** *Speakers: Sujatha Venkataraman*
11:20am – 11:35am	**Viroimmunotherapy for Pediatric Brain Tumors** *Speakers: Candelaria Gomez-Manzano*
11:35am – 11:50am	**Treatment of DIPG with the Oncolytic Zika Virus** *Speakers: Tamarah Westmoreland*
11:50am – 12:05pm	**Unraveling Trancriptional Plasticity as a Non-Genetic Mechanism of Drug Resistance in DMG** *Speakers: Chris Jones*
12:05pm – 12:20pm	**Recognizing the Importance of CD200 in the DMG and HGG Immune Landscape** *Speakers: Christopher Moertel*
12:20pm – 12:35pm	**The Development and Clinical Application of an Effective Anti-Cancer Vaccine for DIPG** *Speakers: Aru Narendran*
12:35pm – 1:00pm	**Lunch Break** sponsored by
1:00pm – 1:15pm	**Adult and Young Adult Perspective: A Panel Discussion** *Speakers: Alexa Huber, Grace Desserich*
1:15pm – 1:30pm	**The End of Animal Testing: A New Era for Pediatric Brain Cancer Research** *Speakers: Daniel Weiner*
1:30pm – 1:45pm	**Designing Clinical Trial Endpoints and Alternative Biopsy and Response Options** *Speakers: Cynthia Hawkins*
1:45pm – 2:30pm	**Packaging Trial Data: Conclusions and Actions** *Speakers: Joga Gobburu, Daniel Weiner*
2:30pm – 2:45pm	**Snack Break** sponsored by

2:45pm – 3:15pm	**The Ethical Dilemma: Designing and Matching Trials to Patients** *Moderators: Jordan Hansford*
3:15pm – 4:15pm	**Building Better Trials with Faster Approvals in Mind** *Moderators: Mark Kieran*
4:15pm – 4:30pm	**Concluding Thoughts** *Speakers: Gavin Baumgardner*

GENERAL MEDULLOBLASTOMA SESSIONS - CASCADE/CONSERVATORY ROOM

6:15am – 7:30am	**Breakfast Available** sponsored by
7:30am – 7:45am	**Medulloblastoma Forum** *Moderators: Nicholas Gottardo*
7:45am – 8:05am	**Posterior Fossa Syndrome** *Speakers: Barry Pizer*
8:05am – 8:25am	**Imaging Features of Posterior Fossa Syndrome** *Speakers: Shivaram Avula*
8:25am – 8:45am	**Neuro-Cognitive Function: The Met Med Trial** *Speakers: Donald Mabbott*
8:45am – 9:05am	**Neuro-Cognitive Rehabilitation and Interventions at St Jude** *Speakers: Heather Conklin*
9:05am – 9:25am	**The St. Jude Experience** *Speakers: Giles Robinson*
9:25am – 9:45am	**Translating CSF Monitoring for Minimal Residual Disease Monitoring to the Clinic** *Speakers: Anthony Liu*
9:45am – 10:15am	**The COG Experience** *Speakers: Nicholas Gottardo*
10:15am – 10:50am	**Medulloblastoma Forum Summary** *Speakers: Amar Gajjar*
10:50am – 11:00am	**Coffee and Tea Break** sponsored by
11:00am – 12:35pm	**Review of Funded Medulloblastoma Research Concepts** *Moderators: Nicholas Gottardo*
11:05am – 11:20am	**Combining FLASH and Immunotherapy to Target Medulloblastoma Relapse** *Speakers: Richard Lu*
11:20am – 11:35am	**Radiation Resistance in Medulloblastoma** *Speakers: Anna Marie Kenney*
11:35am – 11:50am	**Targeting Metabolic Vulnerabilities for Treating Medulloblastoma** *Speakers: Manjeet Rao*
11:50am – 12:05pm	**Targeting rRNA Modification and snoRNA Function** *Speakers: Luiz Penalva*
12:05pm – 12:20pm	**Characterizing and Targeting ABL1 and ABL2 in Medulloblastoma Leptomeningeal Dissemination** *Speakers: Eric Thompson*
12:20pm – 12:35pm	**Dual Targeting Processive Transcription for MYC-Driven Circuitry in Medulloblastoma** *Speakers: Nathan Dahl*
12:35pm – 1:00pm	**Lunch Break** sponsored by

FAMILIES & FOUNDATIONS - CASCADE/CONSERVATORY ROOM

1:00pm – 2:30pm	**Research Recap** *Speakers: Trent Hummel*
2:30pm – 2:45pm	**Snack Break** sponsored by
2:45pm – 4:00pm	**Research Recap** *Speakers: Trent Hummel*

TICKET ONLY EVENTS

6:15am – 7:30am	**International DIPG/DMG Registry Steering Committee**	Norquay Room
8:00am – 10:50am	**Packaging Trial Data Workshop**	Ivor Petrak Room
11:00am – 12:35pm	**Packaging Trial Data Workshop**	Ivor Petrak Room
5:00pm – 9:00pm	**Founders' Banquet Dinner** sponsored by THE CURE STARTS NOW	Van Horne Ballroom



choose JOY for Melina

The Melina Michelle Edenfield Foundation

The Melina Michelle Edenfield Foundation was established in 2020 after a DMG brain tumor took the life of sweet Melina Michelle Edenfield, who was just 4 1/2 years old.

The Foundation, started by Melina's parents, Michelle and Keith Edenfield, is dedicated to raising awareness and finding a cure for DMG/DIPG brain tumors, as well as spreading the message of JOY which Melina brought to so many.

With a dedicated board of 12 volunteer members, the Canfield, Ohio-based Foundation has raised $1.4 million dollars to date and shows no signs of slowing down, hosting over four major fundraisers per year.

www.mmefoundationjoy.org

@mmefoundationjoy

@mmefoundationjoy

LOVE MELINA

THE MELINA MICHELLE EDENFIELD FOUNDATION
P.O. Box 34
Canfield, OH 44406

MONDAY, JULY 28

Transport shuttle schedule:
6:45am - From Hotel Canoe lobby to Fairmont
11:30am - From Fairmont lobby to Hotel Canoe

We recommend using the earlier shuttle to avoid capacity issues as there are limited shuttles.

COLLABORATIVE WORKSHOPS


7:00am – 7:30am	**Breakfast Available** sponsored by	Theater
7:30am – 8:00am	**State of the Collaborative** *Speakers: Steve Healey*	Theater
8:00am – 8:30am	**Research Trends: What to Watch in the Next 5 Years** *Speakers: Keith Desserich*	Theater
8:30am – 9:30am	**Charitable Trends** *Speakers: Brooke Desserich*	Theater
9:30am – 10:00am	**Joint Fundraising and Social Media Campaigns** *Speakers: Tamara Ekis, Steve Healey*	Theater
10:00am – 10:30am	**Best Practices** *Speakers: Steve Healey, Tamara Ekis*	Theater
10:30am – 11:00am	**Open Discussion**	Theater
11:00am – 11:30am	**Conclusion**	Theater

REGISTRY WORKSHOPS

7:00am – 7:30am	**Breakfast Available** sponsored by	Ivor Petrak Room
7:30am – 11:30am	**Registry Workshop**	Ivor Petrak Room

Agenda is subject to change. The printed version may differ from the online version. If there is a discrepancy, please refer to the online version of the agenda.

SCAN TO VIEW THE ONLINE AGENDA



Aubreigh Nicholas

AN ARMY OF HOPE
inspired by Aubreigh.

Aubreigh's Army Foundation 328 is a Leadership Partner of the DIPG/DMG Collaborative and a Gold Sponsor of the International DIPG/DMG Symposium.

We have personally been affected by the deadliest form of childhood cancer: Diffuse Intrinsic Pontine Glioma (DIPG). As a 501(c)(3) foundation, we are determined to fight this terrible illness by raising funds for childhood brain tumor research.

For more information, or to join our Army, please visit us on our website or Facebook page.

AAF328.ORG

1-251-401-8120
Mobile, Alabama


AUBREIGH'S ARMY FOUNDATION 328

AGORA
OPEN SCIENCE TRUST

Redefining Pharmaceutical Innovation Through Open Science

M4K PHARMA

Charity: www.agoraopensciencetrust.org Project: www.m4kpharma.org



Reflections Of Grace Foundation

a founding member of the DIPG/DMG Collaborative and Visionary Partner

DIPG/DMG Collaborative VISIONARY PARTNER 2025 Member

DIPG/DMG COLLABORATIVE

@ReflectsOfGrace · www.reflectionsofgrace.org · info@reflectionsofgrace.org

Whitley's Wishes

www.whitleyswishes.org

"I wish no one ever got cancer."

Whitley's Wishes was created in memory of Whitley Sue Hedger who died from DIPG in 2015. It is our mission to find a cure for this horrible disease and make Whitley's wish come true!



10 YEARS



AIDAN'S AVENGERS

Fighting the Battle Against Pediatric Brain Cancer

Aidan Dunion was 3 years old when diagnosed with DIPG. He passed in August 2014, 10 months after his diagnosis. His spirit lives on through Aidan's Avengers, now in our 10th year as a foundation.

Aidan was an endearing child; his smile and laughter were contagious, and he brought so much joy, laughter, and love in the short amount of time he was with us. His strength, love, and fighting spirit continue to give us the determination to build upon his legacy and make a difference in the fight against DIPG.

As a proud member of the Collaborative, we stand united in our mission to conquer DIPG. Together, we are stronger.

LEARN MORE

AIDAN'S AVENGERS

AidansAvengers.com
info@aidansavengers.com
Follow us @AidansAvengers
Forever 4 in our Hearts



Australis
PHARMACEUTICALS

Harnessing nature to fight cancer

RUN DIPG

RUN DIPG directly supports groundbreaking projects, cutting-edge equipment, and the brightest scientific minds to drive progress against DIPG/DMG.

Learn more about our story

@rundipg

#MovingTowardsACure



ZephaPharm

ZP448 Fixing the Achilles Heel of Mebendazole with Fluvoxamine

Mebendazole MBZ	Preclinically highly active vs. brain tumors - but rapid metabolism of MBZ in humans
Fluvoxamine FLUV	FLUV is a PK enhancer of MBZ with its own preclinical anti-glioblastoma activity
ZP448 MBZ + FLUV	Working to optimize MBZ duration of tumor engagement, PKPD enhancement with FLUV
ZP448 Partnership	Extensive Patents / Partnership for clinical development to pediatric brain tumor trials
Co-Development	john.taylor@zephapharm.com 011 44 7795 847576

Cure Brain Cancer Foundation

Finding a cure for brain cancer is our mission.



- The challenge: DIPG/DMG survival rate remains at 0%.
- Our response: Over $10 million invested in paediatric brain cancer research.
- Collaborative effort: Proud member of the DIPG/DMG Collaborative since 2015.
- Our belief: Sustained research investment is the best path to improving outcomes.

@curebraincancer curebraincancer.org.au

EMulate THERAPEUTICS

EMulate Therapeutics (EMTx) has developed a non-sterile, non-invasive, non-thermal, non-ionizing, battery-powered, portable investigational medical device that uses low to ultra-low level (DC-22kHz) frequencies to deliver a signal to slow down cell division. The system emits a low power magnetic field (< 100 mG) that can be applied locally or globally. This device has been tested in both adult GBM and in pediatric DMG/DIPG with encouraging early data. Visit us at https://www.emulatetx.com and corporate@emulatetx.com

Let's change the course of pediatric brain cancer.

We accelerate high-impact research to find a cure for diffuse midline gliomas and other fatal pediatric brain cancers, while supporting patients and families along their journey.

YUVAAN TIWARI
FOUNDATION



SCAN TO LEARN MORE

ytfoundation.org
info@ytfoundation.org

THANK YOU TO THE MEMBERS OF OUR MEDICAL ADVISORY COUNCIL

Gavin Baumgardner, DO, Chair
Oren Becher, MD
Shana Coley, MD, PHD
Amar Gajjar, MD
Stewart Goldman, MD
Nicholas Joseph Gottardo, MB, CHB, FRACP, PHD
Adam Green, MD
Rintaro Hashizume, MD, PHD
Timothy E G Hassall, MBBS, FRACP
Cynthia Hawkins, MD, PHD
Daniel McPherson, PHD
Roger J. Packer, MD
Ralph E. Vatner, MD, PHD
Daniel Weiner, PHD

Lauren's Fight for Cure

Lauren's Fight for Cure is a 501(c)(3) non-profit organization established in 2014 under the direction of Lauren Hill herself. Our mission is to raise awareness, fund cutting-edge research through the DIPG Collaborative, and provide meaningful support to young adult DIPG patients and their families.

We offer a range of assistance, including:

- **Gift Card Cups** for newly diagnosed patients at Cincinnati Children's Hospital.
- **Financial Assistance** for monthly bills, medical expenses, and funeral costs.
- **Memory-Making Experiences** to create lasting moments with loved ones.
- **End-of-Life Gifts**
- **Trips** for patients diagnosed after their 18th birthday.

At Lauren's Fight for Cure, we are committed to honoring Lauren's legacy by bringing hope, comfort, and resources to those impacted by DIPG.

DIPG.org | TRIAL FINDER Medulloblastoma Resource Network | TRIAL FINDER

Showing **ALL** relevant trials worldwide, allowing **YOU** to discuss all options with your doctor.

Made by **PARENTS** for **PARENTS** and **PATIENTS.**



- Free doctor consult (for DIPG/DMG)
- Enrollment in the largest global DIPG/DMG Registry (for DIPG/DMG)
- Customizable Trial Finder

DIPG/DMG Trial Finder

Medulloblastoma Trial Finder



ROBERT CONNOR DAWES RCD Foundation HELPING KIDS WITH BRAIN CANCER

Our vision **THROUGH OUR LEADERSHIP, ENABLE EVERY PAEDIATRIC BRAIN CANCER PATIENT TO RECEIVE THE BEST GLOBAL TREATMENT**

Robert Connor Dawes Foundation is a not-for-profit organisation headquartered in Australia with an office in the United States. The foundation was created in June 2013 by Liz Dawes and Scott Dawes in memory of their son Robert Connor Dawes who died from a brain tumour in April 2013 at 18 years of age.

OUR MISSION

Our mission is to drive global paediatric brain cancer research advancements and support young patients while they are on their brain cancer journey. We achieve this through investing in Research, Care and Development.



Robert Connor Dawes

Research

We have raised over AU$17.3 M to support paediatric brain cancer research, funding basic science, translational projects, clinical trials, fellowships, scholarships and travel grants. We partner with like-minded, passionate organisations to achieve greater impact and have leveraged another AU$11.4 M through collaborative research initiatives.

We are active members of the

- **DIPG collaborate**
- **Child's Brain Tumour Network (CBTN)**
- **Paediatric Neuro-Oncology Consortium (PNOC)**
- **Collaborative Ependymoma Research Network (CERN)**

Care

We support infants, children, adolescent and young adults with brain cancer and their families or carers with in-home music therapy across Australia. Our qualified therapists have helped over 150 patients at different stages of their journey. We are about to begin a pilot program in the US with Wisconsin being the first area.

Development

Workforce capacity in this field is a challenge, and we want to be part of the solution. Building and inspiring the next generation of paediatric brain cancer researchers and clinicians, we have funded 5 PhD students and 9 postdoctoral scientists to date.

FOR MORE INFORMATION

Dr Kim Wark kimwark@rcdfoundation.org for research

Ms Annette Baron music@rcdfoundation.org for music therapy program.

Rcdfoundation.org

NOTES



THECURESTARTSNOW®

To all of our chapters and families that make funding critical, innovative research possible...

THANK YOU!



WE NEED YOUR BIG IDEAS

The Cure Starts Now follows an extensive grant approval process to ensure your dollars make the biggest impact to homerun cancer research. Take comfort in knowing that The Cure Starts Now only funds: research that follows our mission, is non-duplicative, and is financially sound. We currently have **three different grant opportunities ranging from $50,000-$1,000,000** for research that falls under this criteria.

Learn more about our process and grants that have been funded at **thecurestartsnow.org/grants**

DIPG/DMG COLLABORATIVE

VISIONARY PARTNERS

LEADERSHIP PARTNERS

RESEARCH PARTNERS

SPONSORS

SCAN TO VIEW THE ONLINE AGENDA